Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Janet Rader to Drug Administration Schedule

This is a "connection" page, showing publications Janet Rader has written about Drug Administration Schedule.

 
Connection Strength
 
 
 
0.318
 
  1. Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul; 130(1):64-8.
    View in: PubMed
    Score: 0.103
  2. Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010 Mar; 116(3):438-41.
    View in: PubMed
    Score: 0.081
  3. Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Feb; 76(2):204-7.
    View in: PubMed
    Score: 0.041
  4. Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008 May-Jun; 18(3):400-6.
    View in: PubMed
    Score: 0.017
  5. Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2006 Nov; 103(2):637-41.
    View in: PubMed
    Score: 0.016
  6. Armstrong DK, Blessing JA, Rader J, Sorosky JI. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest New Drugs. 2003 Nov; 21(4):453-7.
    View in: PubMed
    Score: 0.013
  7. Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Ann Oncol. 2002 Nov; 13(11):1819-25.
    View in: PubMed
    Score: 0.012
  8. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002 Apr 01; 20(7):1832-7.
    View in: PubMed
    Score: 0.012
  9. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
    View in: PubMed
    Score: 0.012
  10. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 1997 Sep; 66(3):480-6.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.